ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Acumen Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.77+0.08 (+4.73%)
Close on Oct 19, 2026
- Market cap
- $127.88M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.26 (−12.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $127.88M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.23
- Dividend yield
- –
- Free cash flow yield
- -71.77%
Fundamentals
- Net income
- -$105.04M
- EPS, diluted
- -$1.63
- Free cash flow
- -$91.79M
- Book value per share
- $0.79
- Diluted shares
- 72M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$105.42M
Net income
-$105.04M
EPS, diluted
-$1.63
Free cash flow
-$91.79M
Reported periodTrailing twelve months